Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and ...
Rami Owera, MD, medical oncologist and hematologist with Woodlands Specialty Physicians, a division of Florida Cancer ...
Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung ...
SystImmune, Inc., a clinical-stage biotechnology company, today announced the oral presentation of Phase 1 data for BL-M14D1 ...
Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
Lung cancer took tech executive Susan Wojcicki's life. Now her family has started a foundation as a “catalyst for change.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results